The FDA's new draft IVD Guidelines will need to be factored into how pharma clinical trial sponsors use IVDs in a clinical trial, study design, timeline for protocol development, IND submission, and study initiation.
Michele L. Buenafe
Advertisement
Articles by Michele L. Buenafe
Advertisement
Latest Updated Articles
- What Pharma Companies Need to Know About FDA's New Draft IVD Guidance
Published: February 12th 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Are Clinical Trial Diversity Initiatives at Risk of Being Dismantled?
2
Answering the Sustainability Call: Digital Health Technologies and eCOA
3
Addressing Preclinical Gaps to Prevent Biotech Trial Delays
4
KRI Overload: When More Isn’t Better
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
